Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway

被引:135
作者
Thoennissen, N. H. [1 ]
O'Kelly, J. [1 ]
Lu, D. [1 ]
Iwanski, G. B. [1 ]
La, D. T. [1 ]
Abbassi, S. [1 ]
Leiter, A. [1 ]
Karlan, B. [2 ]
Mehta, R. [3 ]
Koeffler, H. P. [1 ]
机构
[1] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, Los Angeles, CA 90048 USA
[2] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90048 USA
[3] IIT, Res Inst, Div Carcinogenesis & Chemoprevent, Chicago, IL 60616 USA
关键词
capsaicin; EGFR/HER-2; pathway; cell-cycle arrest; apoptosis; ACTIVATED PROTEIN-KINASE; RECEPTOR-GAMMA; GROWTH; INDUCTION; RESISTANCE; HER2; PHOSPHORYLATION; DEGRADATION; ANTAGONISTS; INHIBITORS;
D O I
10.1038/onc.2009.335
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide) is an ingredient of chili peppers with inhibitory effects against cancer cells of different origin. We examined the activity of capsaicin on breast cancer cells in vitro and in vivo. The drug potently inhibited growth of ER-positive (MCF-7, T47D, BT-474) and ER-negative (SKBR-3, MDA-MB231) breast cancer cell lines, which was associated with G(0)/G(1) cell-cycle arrest, increased levels of apoptosis and reduced protein expression of human epidermal growth factor receptor (EGFR), HER-2, activated extracellular-regulated kinase (ERK) and cyclin D1. In contrast, cell-cycle regulator p27(KIP1), caspase activity as well as poly-ADP ribose polymerase (PARP) cleavage were increased. Notably, capsaicin blocked breast cancer cell migration in vitro and decreased by 50% the size of MDA-MB231 breast cancer tumors growing orthotopically in immunodeficient mice without noticeable drug side effects. in vivo activation of ERK was clearly decreased, as well as expression of HER-2 and cyclin D1, whereas caspase activity and PARP cleavage products were increased in tumors of drug-treated mice. Besides, capsaicin potently inhibited the development of preneoplastic breast lesions by up to 80% without evidence of toxicity. Our data indicate that capsaicin is a novel modulator of the EGFR/HER-2 pathway in both ER-positive and-negative breast cancer cells with a potential role in the treatment and prevention of human breast cancer. Oncogene (2010) 29, 285-296; doi:10.1038/onc.2009.335; published online 26 October 2009
引用
收藏
页码:285 / 296
页数:12
相关论文
共 37 条
[1]   Vanilloid receptor agonists and antagonists are mitochondrial inhibitors: How vanilloids cause non-vanilloid receptor mediated cell death [J].
Athanasiou, Andriani ;
Smith, Paul A. ;
Vakilpour, Sara ;
Kumaran, Nethia M. ;
Turner, Amy E. ;
Bagiokou, Dimitra ;
Layfield, Robert ;
Ray, David E. ;
Westwell, Andrew D. ;
Alexander, Stephen P. H. ;
Kendall, David A. ;
Lobo, Dileep N. ;
Watson, Susan A. ;
Lophatanon, Artitaya ;
Muir, Kenneth A. ;
Guo, De-an ;
Bates, Timothy E. .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 354 (01) :50-55
[2]   Co-opted integrin signaling in ErbB2-induced mammary tumor progression [J].
Carraway, Kermit L., III ;
Sweeney, Colleen .
CANCER CELL, 2006, 10 (02) :93-95
[3]   Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors [J].
Chen, Franklin L. ;
Xia, Wenle ;
Spector, Neil L. .
CLINICAL CANCER RESEARCH, 2008, 14 (21) :6730-6734
[4]  
*COUNC EUR, 2001, 48 M STRASB 2 6 APR
[5]   Involvement of ras activation in human breast cancer cell signaling, invasion, and anoikis [J].
Eckert, LB ;
Repasky, GA ;
Ülkü, AS ;
McFall, A ;
Zhou, H ;
Sartor, CI ;
Der, CJ .
CANCER RESEARCH, 2004, 64 (13) :4585-4592
[6]  
Fukazawa H, 2002, MOL CANCER THER, V1, P303
[7]  
Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1
[8]  
Hail N, 2002, JNCI-J NATL CANCER I, V94, P1281, DOI 10.1093/jnci/94.17.1281
[9]   Induction of apoptosis in leukemic cells by homovanillic acid derivative, capsaicin, through oxidative stress: Implication of phosphorylation of p53 at Ser-15 residue by reactive oxygen species [J].
Ito, K ;
Nakazato, T ;
Yamato, K ;
Miyakawa, Y ;
Yamada, T ;
Hozumi, N ;
Segawa, K ;
Ikeda, Y ;
Kizaki, M .
CANCER RESEARCH, 2004, 64 (03) :1071-1078